From ad-hoc-news.de
()
CEO Fred Hassan
CEO Fred Hassan has been the chief executive officer of Schering-Plough Corp since 2003. He is 60 years old. Follow Mr. Hassan and Schering-Plough Corp in the news and blogs or share your own opinion about the company and its leadership.
Celgene Corporation (NASDAQ: CELG) announced the election of Carrie S Cox to the Company?s Board of Directors Ms Cox is an experienced corporate director with a distinguished career in global healthcare She has served as executive vice president and president of Schering-Plough's Global Pharmaceutical Business, one of the largest and most successful multi-national healthcare companies in the world Before joining Schering-Plough, Ms.
- Robert J. Bertolini Elected to Genzyme’s Board of Directors (businesswire.com)
- Merck completes $41B purchase of Schering-Plough (thenewstribune.com)
- Merck-Schering deal complete (philly.com)
NEW YORK--(BUSINESS WIRE)--Time Warner Inc. (NYSE: TWX) announced that its Board of Directors has elected Fred Hassan to join the Board, effective today. Mr. Hassan, 63, is Chairman of the Board and Chief Executive Officer of Schering-Plough Corporation. Jeff Bewkes, Chairman and CEO of Time Warner, said: “Fred Hassan is an experienced CEO who brings to our Board more than 15 years of leading large, global companies. He’ll also bring valuable...
From businesswire.com
()
- Fred Hassan Joins Warburg Pincus (feedburner.com)
- Fred Hassan: A Sunrise Industry: Life Sciences and the Genomics Wave (huffingtonpost.com)
- Reuters Summit: Hassan sees Merck retaining Remicade (rehabpub.com)
Merck & Co. and Santarus Inc. said Tuesday the Food and Drug Administration approved Merck's over-the-counter version of the Santarus prescription heartburn drug Zegerid. San Diego-based Santarus had partnered with Schering-Plough Corp. on the over-the-...
Food and Drug Administration - Schering-Plough - Merck & Co - United States - Over-the-counter drug
More perspectives...
From sfgate.com
()
Merck & Co. Inc. has outlined its global plans following the completion of Merck's merger with Schering-Plough Corporation.
"With our merger now complete, we are ready to deliver on the promise of a new Merck built on a foundation...
From thehorse.com
()
- FTC approves Merck-Schering-Plough deal (philly.com)
- Merck, Schering Plough mergers clears FTC hurdle (veterinarynews.dvm360.com)
- Merck, Schering Plough merger clears FTC hurdle (veterinarynews.dvm360.com)
CHICAGO--(BUSINESS WIRE)--As a result of the completed merger between Merck & Co., Inc. (Merck) and Schering-Plough Corp. (Schering-Plough) yesterday, Fitch Ratings has downgraded Merck's Issuer Default Rating (IDR) to 'A+' from 'AA-' and upgraded Schering-Plough's IDR to 'A+' from 'BBB+'. Simultaneously, Fitch downgraded Merck's senior unsecured debt and bank loan ratings to 'A+' from 'AA-' and downgraded the short-term IDR and commercial...
From businesswire.com
()
- Opko Health, Inc. OPK Morning Session 1.73 (irnewsservice.com)



